Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis ...

GSK's six-monthly IL-5 inhibitor depemokimab clears two phase 3 trials in chronic rhinosinusitis with nasal polyps (CRSwNP), its second indication.

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

The committee recalled the potential uncaptured benefits related to the lack of sensitivity of the EQ-5D in severe CRSwNP, and the potential for dupilumab to reduce the need for oral corticosteroids ...